Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.
Tell us about a missing company
Sorrento Therapeutics, Inc. clinical trials
The registry lists 46 studies whose lead sponsor is Sorrento Therapeutics, Inc.. 4 are recruiting or about to start. Per ClinicalTrials.gov, last updated Apr 17, 2024.
Keep track of what changes. Save the Sorrento Therapeutics, Inc. studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesRegistry sponsor names on this page
Each name exactly as ClinicalTrials.gov lists it, and how it relates to Sorrento Therapeutics, Inc..
- Sorrento Therapeutics, Inc.46 studiesSame company
Something wrong?
Focus areas
Conditions Sorrento Therapeutics, Inc. leads ten or more studies in, by study count. A broader condition is left out when almost all its studies are already in a narrower one listed here.
Studies
Recruiting first, then most recently updated. Showing 46 of 46.
- Study to Assess the Safety and Preliminary Efficacy of STI-1386 Oncolytic Virus in Relapsed or Refractory Solid TumorsNot yet recruitingNCT05361954Phase 1
- Study to Access Anti-CD38 Anibody Drug in Patients With Advanced Solid TumorsNot yet recruitingNCT05584709Phase 1
- Long-Term Follow-Up of Patients Who Received Gene-Modified Cell TherapyEnrolling by invitationNCT05472649
- Study to Assess Allogeneic Anti-CD38 A2 Dimeric Antigen Receptor T Cells in Relapsed or Refractory Multiple MyelomaRecruitingNCT05007418Phase 1
- Study of Allogeneic Adipose-Derived Mesenchymal Stem Cells to Treat Post COVID-19 "Long Haul" Pulmonary CompromiseWithdrawnNCT04992247Phase 2
- Study to Assess Epidural Resiniferatoxin for the Treatment of Intractable Pain Associated With Advanced CancerSuspendedNCT05067257Phase 2
- Study to Assess Abivertinib in Combination With Abiraterone in Metastatic Castration Resistant Prostate CancerSuspendedNCT05361915Phase 2
- A Study of STI-3031 (an Anti-PD-L1 Antibody) in Patients With Selected Relapsed/Refractory MalignanciesWithdrawnNCT03999658Phase 2
- An Open-Label Study of the Safety of an Anti-CD38 Antibody Drug Conjugate (STI-6129) in Patients With AL AmyloidosisWithdrawnNCT05692908Phase 1
- Study to Assess Anti-CD38 Antibody Drug Conjugate in Relapsed or Refractory Multiple MyelomaActive, not recruitingNCT05308225Phase 1/2
- Study to Assess the Safety and Efficacy of Enbrel Administered by Sofusa DoseConnect for Rheumatoid ArthritisStatus unknownNCT04559412Phase 1
- Study to Evaluate the Efficacy of IN STI-9199 in Treating Symptomatic COVID-19 in Outpatient Adults and AdolescentsWithdrawnNCT05372783Phase 2
- Study to Assess the Safety, Tolerability and Pharmacokinetics of STI-1558 in Healthy VolunteersCompletedNCT05364840Phase 1
- Study to Evaluate a Single Intranasal Dose of STI-2099 (COVI-DROPS™) in Outpatient Adults With COVID-19 (UK)TerminatedNCT04900428Phase 2
- Study to Assess an Anti-Trop2 Antibody Drug Conjugate in Relapsed or Refractory Solid TumorsWithdrawnNCT05060276Phase 1
- Study of the Efficacy and Safety of STI-5656 (Abivertinib Maleate) in Subjects Hospitalized With COVID-19CompletedNCT04440007Phase 2
- Phase 1b Study of CAR2Anti-CEA CAR-T Cell Hepatic Infusions for Pancreatic Carcinoma Patients With CEA+ Liver MetastasesTerminatedNCT03818165Phase 1
- Study to Evaluate Intra-articular Resiniferatoxin to Treat Moderate to Severe Pain From Knee OsteoarthritisStatus unknownNCT04885972Phase 2
- Study of the Safety and Efficacy of STI-6643 in Subjects With Advanced Solid TumorsStatus unknownNCT04900519Phase 1
- Study of the Safety and Efficacy of STI-6129 in Patients With Relapsed or Refractory Systemic AL AmyloidosisStatus unknownNCT04316442Phase 1/2
- Study of Intravenous COVI-MSC for Treatment of COVID-19-Induced Acute Respiratory DistressTerminatedNCT04903327Phase 2
- Pembrolizumab Administered Via the Sofusa® DoseConnect™ in Patients With Relapsed/Refractory Cutaneous T-cell Lymphoma.Status unknownNCT04118868Phase 1
- Study to Evaluate a Single Dose of STI-2020 (COVI-AMG™) in Hospitalized Adults With COVID-19WithdrawnNCT04771351Phase 2
- Sofusa System With Sumatriptan (KC5010) Phase 1 Dose Escalation Safety and PK Study (KCC-SMT-002)CompletedNCT03229798Phase 1
- Study of Allogeneic Adipose-Derived Mesenchymal Stem Cells for Treatment of COVID-19 Acute Respiratory DistressStatus unknownNCT04905836Phase 2
- CAR-T Intraperitoneal Infusions for CEA-Expressing Adenocarcinoma Peritoneal Metastases or Malignant Ascites (IPC)WithdrawnNCT03682744Phase 1
- Study of Anti-CEA CAR-T + Chemotherapy VS Chemotherapy Alone in Patients With CEA+Pancreatic Cancer & Liver MetastasesWithdrawnNCT04037241Phase 2/3
- Study of STI-3031 in Patients With Selected Relapsed or Refractory Solid TumorsWithdrawnNCT04809012Phase 2
- Study of Intravenous Administration of Allogeneic Adipose Stem Cells for COVID-19CompletedNCT04486001Phase 1
- Study to Evaluate the Safety and Efficacy of Anti-CD38 CAR-T in Relapsed or Refractory Multiple Myeloma PatientsCompletedNCT03464916Phase 1
- Study to Evaluate a Single Dose of STI-2020 (COVI-AMG™) in Adults With Mild COVID-19 SymptomsWithdrawnNCT04734860Phase 2
- Study to Evaluate the Safety and Efficacy of a Single Dose of STI-2020 (COVI-AMG™) to Treat COVID-19WithdrawnNCT04738175Phase 1/2
- Randomized Study to Evaluate Intranasal Dose of STI-2099 (COVI-DROPS™) in Outpatient Adults With Mild COVID-19 InfectionWithdrawnNCT05074394Phase 2
- Study to Evaluate a Single Intranasal Dose of STI-2099 (COVI-DROPS™) in Outpatient Adults With COVID-19 (US)CompletedNCT04906694Phase 2
- Phase 3 Study to Assess Resiniferatoxin vs Standard of Care for the Treatment of Intractable Cancer PainWithdrawnNCT04572776Phase 3
- Study to Evaluate Resiniferatoxin in Patients With Knee Osteoarthritis Whose Total Knee Replacement Surgery is DelayedWithdrawnNCT04386980Phase 3
- A Phase 3 Study to Evaluate the Efficacy and Safety of Resiniferatoxin for Pain Due to Osteoarthritis of the KneeWithdrawnNCT04044742Phase 3
- Study of the Safety and Efficacy of STI-5656 (Abivertinib Maleate) in Subjects Hospitalized Due to COVID-19CompletedNCT04528667Phase 2
- Study of Allogeneic Adipose-Derived Mesenchymal Stem Cells for Non-COVID-19 Acute Respiratory Distress SyndromeWithdrawnNCT04909879Phase 2
- Study of Allogeneic Adipose-Derived Mesenchymal Stem Cells to Treat Post COVID-19 "Long Haul" Pulmonary CompromiseWithdrawnNCT04909892Phase 2
- Study of Intravenous Administration of Allogeneic Adipose-Derived Mesenchymal Stem Cells for COVID-19-Induced Acute Respiratory DistressWithdrawnNCT04728698Phase 2
- Study of Resiniferatoxin for Knee Pain in Moderate to Severe OsteoarthritisCompletedNCT03542838Phase 1
- Study to Evaluate the Safety, Pharmacokinetics and Efficacy of STI-2020 (COVI-AMG™) in Outpatients With COVID-19WithdrawnNCT04584697Phase 1/2
- Study to Evaluate STI-1499 (COVI-GUARD) in Patients With Moderate COVID-19WithdrawnNCT04454398Phase 1
- Study to Evaluate Safety and MTD of Epidural Resiniferatoxin Injection for Treatment of Intractable Cancer PainCompletedNCT03226574Phase 1
- Bioequivalence Study of IG-001 Versus Nab-paclitaxel in Metastatic or Locally Recurrent Breast CancerCompletedNCT02064829Not applicable